Evolutionary and Microenvironmental Determinants of Therapeutic Resistance: Integrative Frameworks for Dynamic Precision Oncology
DOI:
https://doi.org/10.64784/149Keywords:
Tumor adaptation, Therapeutic resistance, Intratumoral heterogeneity, Clonal evolution, Targeted therapy resistance, Immunotherapy resistance, Immune checkpoint blockade, Tumor microenvironment, Cancer stem cell niche, Genome-driven oncology, Precision oncology, Evolutionary oncology, Immune editing, Signaling plasticity, Translational oncologyAbstract
Tumor adaptation and therapeutic resistance remain central challenges in modern oncology despite significant advances in targeted therapy and immunotherapy. Contemporary evidence indicates that resistance is not an isolated pharmacologic failure but an emergent property of evolving tumor ecosystems characterized by intratumoral heterogeneity, clonal selection, immune modulation, and tumor microenvironmental support. This review synthesizes landmark mechanistic and translational studies to construct an integrated framework linking evolutionary dynamics, signaling plasticity, immune escape, and precision oncology implementation. Across targeted therapies, resistance frequently develops through pathway reactivation, bypass signaling, and adaptive rewiring under selective pressure. In immunotherapy, resistance involves immune editing, checkpoint regulation complexity, impaired antigen presentation, and stromal-mediated immune exclusion. The tumor microenvironment further stabilizes therapy-tolerant populations through niche protection and cytokine-driven suppression. Genome-driven oncology provides a translational pathway for personalization; however, effective precision strategies must be dynamic and iterative, accounting for tumor evolution rather than relying on static baseline profiling. This integrative perspective supports improved therapeutic reasoning, multidisciplinary decision-making, and context-adapted implementation in diverse healthcare systems, including emerging oncology infrastructures in Latin America. Understanding resistance as an evolutionary and ecological phenomenon strengthens both clinical strategy design and advanced oncology education.
References
Bedard, P. L., Hansen, A. R., Ratain, M. J., & Siu, L. L. (2013). Tumour heterogeneity in the clinic. Nature, 501(7467), 355–364. https://doi.org/10.1038/nature12627
Burrell, R. A., McGranahan, N., Bartek, J., & Swanton, C. (2013). The causes and consequences of genetic heterogeneity in cancer evolution. Nature, 501(7467), 338–345. https://doi.org/10.1038/nature12625
Dagogo-Jack, I., & Shaw, A. T. (2018). Tumour heterogeneity and resistance to cancer therapies. Nature Reviews Clinical Oncology, 15(2), 81–94. https://doi.org/10.1038/nrclinonc.2017.166
Dienstmann, R., Rodon, J., Barretina, J., & Tabernero, J. (2013). Genomic medicine frontier in human solid tumors. Journal of Clinical Oncology, 31(15), 1874–1884. https://doi.org/10.1200/JCO.2012.45.1419
Garraway, L. A., & Jänne, P. A. (2012). Circumventing cancer drug resistance. Cancer Discovery, 2(3), 214–226. https://doi.org/10.1158/2159-8290.CD-12-0012
Hanahan, D. (2022). Hallmarks of cancer: New dimensions. Cancer Discovery, 12(1), 31–46. https://doi.org/10.1158/2159-8290.CD-21-1059
Holohan, C., Van Schaeybroeck, S., Longley, D. B., & Johnston, P. G. (2013). Cancer drug resistance: An evolving paradigm. Nature Reviews Cancer, 13(10), 714–726. https://doi.org/10.1038/nrc3599
Hyman, D. M., Taylor, B. S., & Baselga, J. (2017). Implementing genome-driven oncology. Cell, 168(4), 584–599. https://doi.org/10.1016/j.cell.2016.12.015
June, C. H., O’Connor, R. S., Kawalekar, O. U., et al. (2018). CAR T cell immunotherapy for human cancer. Science, 359(6382), 1361–1365. https://doi.org/10.1126/science.aar6711
Mariathasan, S., Turley, S. J., Nickles, D., et al. (2018). TGFβ attenuates tumour response to PD-L1 blockade. Nature, 554(7693), 544–548. https://doi.org/10.1038/nature25501
McGranahan, N., & Swanton, C. (2017). Clonal heterogeneity and tumor evolution. Cell, 168(4), 613–628. https://doi.org/10.1016/j.cell.2017.01.018
O’Donnell, J. S., Teng, M. W. L., & Smyth, M. J. (2019). Cancer immunoediting and resistance to immunotherapy. Nature Reviews Clinical Oncology, 16(3), 151–167. https://doi.org/10.1038/s41571-018-0142-8
Plaks, V., Kong, N., & Werb, Z. (2015). The cancer stem cell niche: How essential is the niche in regulating stemness? Cell Stem Cell, 16(3), 225–238. https://doi.org/10.1016/j.stem.2015.02.015
Roma-Rodrigues, C., Mendes, R., Baptista, P. V., & Fernandes, A. R. (2019). Targeting tumor microenvironment for cancer therapy. International Journal of Molecular Sciences, 20(4), 840. https://doi.org/10.3390/ijms20040840
Sharma, P., & Allison, J. P. (2015). The future of immune checkpoint therapy. Science, 348(6230), 56–61. https://doi.org/10.1126/science.aaa8172
Sun, C., Mezzadra, R., & Schumacher, T. N. (2018). Regulation and function of the PD-L1 checkpoint. Nature Reviews Immunology, 18(12), 685–698. https://doi.org/10.1038/s41577-018-0068-0
Topalian, S. L., Drake, C. G., & Pardoll, D. M. (2015). Immune checkpoint blockade: A common denominator approach to cancer therapy. Cancer Cell, 27(4), 450–461. https://doi.org/10.1016/j.ccell.2015.03.001
Turajlic, S., & Swanton, C. (2016). Metastasis as an evolutionary process. Science, 352(6282), 169–175. https://doi.org/10.1126/science.aaf2784
Turner, N. C., & Reis-Filho, J. S. (2012). Genetic heterogeneity and cancer drug resistance. The Lancet Oncology, 13(4), e178–e185. https://doi.org/10.1016/S1470-2045(11)70335-7
Vasan, N., Baselga, J., & Hyman, D. M. (2019). A view on drug resistance in cancer. Nature, 575(7782), 299–309. https://doi.org/10.1038/s41586-019-1730-1
